Immune Cells Enter the Brain After Stroke and Promote Blood Vessel Repair via CGRP

ILC2 immune cells infiltrate the brain after stroke and promote new blood vessel growth through α-CGRP production, improving long-term recovery.

Ping, An et al.·The Journal of experimental medicine·2025·lowAnimal StudyAnimal Study
RPEP-13058Animal Studylow2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
low
Sample
N=Not reported (mouse study)
Participants
Mouse ischemic stroke model

What This Study Found

ILC2s infiltrate the brain post-stroke via CXCR1 and produce α-CGRP that initiates angiogenic sprouting, improving long-term functional recovery.

Key Numbers

ILC2s enter brain parenchyma via CXCR1 after ischemic stroke. Alpha-CGRP production by ILC2s required for angiogenic sprouting. CGRP-depleted ILC2s failed to initiate angiogenesis. CGRP receptor impairment on endothelial cells abolished the effect.

How They Did This

In vivo and in vitro ILC2 expansion studies in ischemic stroke mouse models with functional recovery assessment.

Why This Research Matters

Stroke recovery options are limited — harnessing the brain's own immune repair system through ILC2s and CGRP could open new therapeutic pathways.

The Bigger Picture

This reveals CGRP as a brain repair molecule (not just a migraine target), expanding our understanding of how the immune and vascular systems collaborate after brain injury.

What This Study Doesn't Tell Us

Mouse model study — human stroke pathophysiology and immune responses may differ. In vivo ILC2 expansion techniques are not yet clinically available.

Questions This Raises

  • ?Could boosting ILC2 numbers or CGRP levels after stroke improve human outcomes?
  • ?Do anti-CGRP migraine drugs interfere with stroke recovery?

Trust & Context

Key Stat:
α-CGRP Produced by brain-infiltrating ILC2s to initiate angiogenic sprouting after ischemic stroke
Evidence Grade:
Preclinical mouse study with robust mechanistic evidence — highly informative but requires human translation.
Study Age:
Published in 2025, revealing a novel neuroimmune repair mechanism post-stroke.
Original Title:
Brain-infiltrating ILC2s boost poststroke angiogenic initiation through α-CGRP production.
Published In:
The Journal of experimental medicine, 222(11) (2025)
Database ID:
RPEP-13058

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

How do immune cells help repair the brain after stroke?

ILC2 cells enter the brain from the bloodstream and produce CGRP, which triggers new blood vessel growth essential for recovery.

Could this discovery lead to new stroke treatments?

Potentially — boosting ILC2 activity or CGRP production after stroke could become a therapeutic strategy, but human studies are needed first.

Read More on RethinkPeptides

Cite This Study

RPEP-13058·https://rethinkpeptides.com/research/RPEP-13058

APA

Ping, An; Yang, Fan; Lu, Lingxiao; Zhang, Xiaotao; Lu, Jianan; Li, Huaming; Gu, Yichen; Jin, Ziyang; Zhang, Jianmin; Shi, Ligen. (2025). Brain-infiltrating ILC2s boost poststroke angiogenic initiation through α-CGRP production.. The Journal of experimental medicine, 222(11). https://doi.org/10.1084/jem.20241830

MLA

Ping, An, et al. "Brain-infiltrating ILC2s boost poststroke angiogenic initiation through α-CGRP production.." The Journal of experimental medicine, 2025. https://doi.org/10.1084/jem.20241830

RethinkPeptides

RethinkPeptides Research Database. "Brain-infiltrating ILC2s boost poststroke angiogenic initiat..." RPEP-13058. Retrieved from https://rethinkpeptides.com/research/ping-2025-braininfiltrating-ilc2s-boost-poststroke

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.